The global cell culture media market size was estimated to be USD 4.96 billion in 2023 and is expected to reach at USD 19.9 billion by 2033 with a CAGR of 13.47% during the forecast period 2023-2033. Increasing demand for biopharmaceuticals, rising demand for cell culture media for the growth of cells or microorganisms used in the manufacturing of biopharmaceuticals, surge in favourable governmental policies, growing investment in research & development activities, increase in scientific innovations particularly in the production & testing of vaccine technology, surge in cell culture technology used to develop cell-based vaccines, and rising approvals of cell-based products by regulatory bodies are some of the key factors boosting the market growth.
Rising approvals of cell-based products by regulatory bodies is predicted to boost the market growth during the forecast period. For instance, in October 2021, Seqirus has received approval from the U.S. Food and Drug Administration (FDA) for an expanded age indication of FLUCELVAX® QUADRIVALENT (Influenza Vaccine), their cell-based quadrivalent influenza vaccine. The vaccine can now be administered to children as young as six months old, making it the first and only cell-based influenza vaccine available in the United States.
By Product, Serum free media was the highest revenue-grossing segment in the global cell culture media market in 2022 owing to improved physiological sensitivity regulation, enhanced development and/or production, reduced risk of culture infection from serum-borne adventitious agents, & more reliable performance, growing field of gene & cell therapy, increasing adoption of serum-free alternatives better serve the animal welfare, and rising launch of serum free media by key market players. For instance, in March 2021, PromoCell GmbH has introduced its enhanced third-generation Melanocyte Cell Culture Portfolio. The portfolio comprises Melanocyte Growth Medium M3, a formulation of medium devoid of serum, bovine pituitary extract (BPE), and phorbol myristate acetate (PMA). Additionally, Chemically defined media is predicted to grow at fastest CAGR during the forecast period owing to the extensive use in a variety of applications due to its ability to provide consistent results across batches and physiologically appropriate settings for different mammalian cell cultures.
By Application, Biopharmaceutical production was the highest revenue-grossing segment in the global cell culture media market in 2022 owing to the growing need for more reproducible & better-defined media to keep up with demand while lowering the possibility of contamination in downstream processes, increasing investment in research & development activities, and surge in strategic initiatives by biopharmaceutical companies. For instance, in July 2021, Cytiva and Pall Corporation have made a significant investment of USD 1.5 billion to address the increasing demand for biotechnology solutions. As part of their investment strategy, the two companies are planning to allocate over USD 400 million specifically for cell culture media in powder or liquid form. They will be expanding their operations in the United States, Austria, and the United Kingdom. Additionally, Drug screening and development is predicted to grow at fastest CAGR during the forecast period owing to the rising demand for cell culture media for the production of vaccines & other therapeutic treatments.
By Type, Liquid media was the highest revenue-grossing segment in the global cell culture media market in 2022 owing to the rising manufacturing of biologics & biosimilars, increasing adoption of liquid media due to the factors such as rapid mycobacterial growth & high isolation rate, growing demand of ready-to-use liquid media, surge in strategic activities by the manufacturers. For instance, in June 2021, Sartorius has inaugurated a new facility in Israel, dedicated to producing tailor-made and specialized cell culture solutions primarily for the advanced therapies sector. The site will play a crucial role in manufacturing buffers and liquid cell culture products on a large scale. Additionally, Solid media is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of solid media due to the factors such as rapid cell growth and growing development of cell-based products.
By End-user, Pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global cell culture media market in 2022 owing to the surge use of single-use technologies, growing number of regulatory approvals for culture-based vaccines, presence of major pharmaceutical & biotechnology market players, and rising expansion of manufacturing capacities for biopharmaceuticals. For instance, in September 2020, Cytiva has revealed its plans to boost manufacturing capacity and workforce recruitment in key sectors to meet the escalating demands of the biotechnology field. The company is set to invest approximately USD 500 million over the course of five years to expand its manufacturing capabilities. Additionally, Research & academic institutes is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities, and growing clinical trials.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising expansion of pharmaceutical & biotechnology industries, surge in approvals for cell culture-based vaccines, increasing prevalence of diseases such as cancer, rising investment in cell-based research, and growing launch of new products by market players. For instance, in April 2023, The BalanCD CHO Media Platform Portfolio for Bioprocessing has been introduced by FUJIFILM Irvine Scientific. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing awareness regarding the use of the cell culture technique, increasing research & development activities, and rising strategic initiatives by market players. For instance, In December 2021, A new bioprocessing facility is being built in China by Fujifilm Irvine Scientific, Inc. The center's primary goal is to provide comprehensive support for optimizing cell culture media in the development of biotherapeutic drugs, vaccines, and advanced therapies.
Rising approvals of cell-based products by regulatory bodies is predicted to boost the market growth during the forecast period. For instance, in October 2021, Seqirus has received approval from the U.S. Food and Drug Administration (FDA) for an expanded age indication of FLUCELVAX® QUADRIVALENT (Influenza Vaccine), their cell-based quadrivalent influenza vaccine. The vaccine can now be administered to children as young as six months old, making it the first and only cell-based influenza vaccine available in the United States.
By Product, Serum free media was the highest revenue-grossing segment in the global cell culture media market in 2022 owing to improved physiological sensitivity regulation, enhanced development and/or production, reduced risk of culture infection from serum-borne adventitious agents, & more reliable performance, growing field of gene & cell therapy, increasing adoption of serum-free alternatives better serve the animal welfare, and rising launch of serum free media by key market players. For instance, in March 2021, PromoCell GmbH has introduced its enhanced third-generation Melanocyte Cell Culture Portfolio. The portfolio comprises Melanocyte Growth Medium M3, a formulation of medium devoid of serum, bovine pituitary extract (BPE), and phorbol myristate acetate (PMA). Additionally, Chemically defined media is predicted to grow at fastest CAGR during the forecast period owing to the extensive use in a variety of applications due to its ability to provide consistent results across batches and physiologically appropriate settings for different mammalian cell cultures.
By Application, Biopharmaceutical production was the highest revenue-grossing segment in the global cell culture media market in 2022 owing to the growing need for more reproducible & better-defined media to keep up with demand while lowering the possibility of contamination in downstream processes, increasing investment in research & development activities, and surge in strategic initiatives by biopharmaceutical companies. For instance, in July 2021, Cytiva and Pall Corporation have made a significant investment of USD 1.5 billion to address the increasing demand for biotechnology solutions. As part of their investment strategy, the two companies are planning to allocate over USD 400 million specifically for cell culture media in powder or liquid form. They will be expanding their operations in the United States, Austria, and the United Kingdom. Additionally, Drug screening and development is predicted to grow at fastest CAGR during the forecast period owing to the rising demand for cell culture media for the production of vaccines & other therapeutic treatments.
By Type, Liquid media was the highest revenue-grossing segment in the global cell culture media market in 2022 owing to the rising manufacturing of biologics & biosimilars, increasing adoption of liquid media due to the factors such as rapid mycobacterial growth & high isolation rate, growing demand of ready-to-use liquid media, surge in strategic activities by the manufacturers. For instance, in June 2021, Sartorius has inaugurated a new facility in Israel, dedicated to producing tailor-made and specialized cell culture solutions primarily for the advanced therapies sector. The site will play a crucial role in manufacturing buffers and liquid cell culture products on a large scale. Additionally, Solid media is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of solid media due to the factors such as rapid cell growth and growing development of cell-based products.
By End-user, Pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global cell culture media market in 2022 owing to the surge use of single-use technologies, growing number of regulatory approvals for culture-based vaccines, presence of major pharmaceutical & biotechnology market players, and rising expansion of manufacturing capacities for biopharmaceuticals. For instance, in September 2020, Cytiva has revealed its plans to boost manufacturing capacity and workforce recruitment in key sectors to meet the escalating demands of the biotechnology field. The company is set to invest approximately USD 500 million over the course of five years to expand its manufacturing capabilities. Additionally, Research & academic institutes is predicted to grow at fastest CAGR during the forecast period owing to the increasing research & development activities, and growing clinical trials.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising expansion of pharmaceutical & biotechnology industries, surge in approvals for cell culture-based vaccines, increasing prevalence of diseases such as cancer, rising investment in cell-based research, and growing launch of new products by market players. For instance, in April 2023, The BalanCD CHO Media Platform Portfolio for Bioprocessing has been introduced by FUJIFILM Irvine Scientific. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing awareness regarding the use of the cell culture technique, increasing research & development activities, and rising strategic initiatives by market players. For instance, In December 2021, A new bioprocessing facility is being built in China by Fujifilm Irvine Scientific, Inc. The center's primary goal is to provide comprehensive support for optimizing cell culture media in the development of biotherapeutic drugs, vaccines, and advanced therapies.
Segmentation: Cell Culture Media Market Report 2022 - 2033
Cell Culture Media Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
- Stem Cell Culture Media
- Chemically Defined Media
- Specialty Media
- Classical Media
Serum-free Media
- Vero Medium
- CHO Media
- HEK 293 Media
- BHK Medium
- Others
- Others
Cell Culture Media Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Drug Screening and Development
- Diagnostics
Tissue Engineering and Regenerative Medicine
- Cell And Gene Therapy
- Others
Biopharmaceutical Production
- Vaccines Production
- Monoclonal Antibodies
- Others
- Others
Cell Culture Media Market Analysis & Forecast by Type 2022 - 2033 (Revenue USD Bn)
- Solid Media
- Semi-solid
- Liquid Media
Cell Culture Media Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Hospitals & Diagnostic Laboratories
- Research & Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Cell Culture Media Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cell Culture Media Market: Product Estimates & Trend Analysis
8. Cell Culture Media Market: Application Estimates & Trend Analysis
9. Cell Culture Media Market: Type Estimates & Trend Analysis
10. Cell Culture Media Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Cell Culture Media Market
13. Europe Global Cell Culture Media Market
14. Asia Pacific Global Cell Culture Media Market
15. Latin America Global Cell Culture Media Market
16. MEA Global Cell Culture Media Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Avantor Performance Materials LLC
- CYTIVA
- Becton
- Dickinson and Company
- Sartorius AG
- Bio-Rad Laboratories Inc.
- FUJIFILM Irvine Scientific Inc.
- Corning Incorporated
- Lonza Group AG
- GE Healthcare
- InvivoGen
- HiMedia Laboratories Pvt. Ltd
- STEMCELL Technologies Inc.
- Merck & Co. Inc.
- PromoCell GmbH
- Thermo Fisher Scientific Inc.
- Cell Biologics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 4.96 Billion |
| Forecasted Market Value ( USD | $ 19.9 Billion |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
